Format

Send to

Choose Destination
Ann Transl Med. 2018 Nov;6(Suppl 1):S62. doi: 10.21037/atm.2018.10.35.

Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?

Author information

1
NRCTC and Newcastle University, The medical school, Farmington place, Newcastle-upon-Tyne, UK.

Conflict of interest statement

Conflicts of Interest: KJ Marchbank is a member of Gemini Therapeutics inc scientific advisor board and is contracted by Idorsia ltd to test agents in the C3 GOF mouse. K Smith-Jackson has no conflicts of interest to declare.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center